Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Rockledge, FL
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Rockledge, FL
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Hazard, KY
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Hazard, KY
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Alexandria, LA
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Alexandria, LA
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Marrero, LA
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Marrero, LA
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Jackson, MS
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Lake Success, NY
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Staten Island, NY
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Staten Island, NY
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Corpus Christi, TX
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
Clinical Research Facility
mi
from
Houston, TX
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated:  2/15/2018
mi
from
Buenos Aires,
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Status: Enrolling
Updated: 2/15/2018
mi
from
Buenos Aires,
Click here to add this to my saved trials
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Status: Enrolling
Updated:  2/15/2018
University of Louisville/James Graham Brown Cancer Center
mi
from
Louisville, KY
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Status: Enrolling
Updated: 2/15/2018
University of Louisville/James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Status: Enrolling
Updated:  2/15/2018
Vanderbilt Heart One Hundred Oaks
mi
from
Nashville, TN
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Status: Enrolling
Updated: 2/15/2018
Vanderbilt Heart One Hundred Oaks
mi
from
Nashville, TN
Click here to add this to my saved trials
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Status: Enrolling
Updated:  2/15/2018
MBCCOP - Meharry Medical College - Nashville
mi
from
Nashville, TN
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Status: Enrolling
Updated: 2/15/2018
MBCCOP - Meharry Medical College - Nashville
mi
from
Nashville, TN
Click here to add this to my saved trials
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Status: Enrolling
Updated:  2/15/2018
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Status: Enrolling
Updated: 2/15/2018
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors
Facilitating Motivational Readiness and Adoption of Physical Activity by Breast Cancer Survivors With a Smart Phone Application
Status: Enrolling
Updated:  2/19/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors
Facilitating Motivational Readiness and Adoption of Physical Activity by Breast Cancer Survivors With a Smart Phone Application
Status: Enrolling
Updated: 2/19/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.
Status: Enrolling
Updated:  2/20/2018
University of Miami
mi
from
Miami, FL
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.
Status: Enrolling
Updated: 2/20/2018
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.
Status: Enrolling
Updated:  2/20/2018
Universitäts-Frauenklinik
mi
from
Göttingen,
Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.
Status: Enrolling
Updated: 2/20/2018
Universitäts-Frauenklinik
mi
from
Göttingen,
Click here to add this to my saved trials
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
A Pilot Study of the Clinical Implementation of the Carevive Survivor Care Planning System
Status: Enrolling
Updated:  2/20/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
A Pilot Study of the Clinical Implementation of the Carevive Survivor Care Planning System
Status: Enrolling
Updated: 2/20/2018
Sidney Kimmel Cancer Center - Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
A Pilot Study of the Clinical Implementation of the Carevive Survivor Care Planning System
Status: Enrolling
Updated:  2/20/2018
Reading Hospital
mi
from
Reading, PA
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
A Pilot Study of the Clinical Implementation of the Carevive Survivor Care Planning System
Status: Enrolling
Updated: 2/20/2018
Reading Hospital
mi
from
Reading, PA
Click here to add this to my saved trials
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
The Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Metastatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial
Status: Enrolling
Updated:  2/20/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.
The Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Metastatic Breast Cancer Patients Previously Responsive to Hormonal Therapy: A Phase II Trial
Status: Enrolling
Updated: 2/20/2018
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Bay Area Tumor Institute
mi
from
Oakland, CA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Exempla Saint Joseph Hospital
mi
from
Denver, CO
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Exempla Saint Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Delaware Clinical & Laboratory Physicians, PA
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Delaware Clinical & Laboratory Physicians, PA
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Helen F. Graham Cancer Center
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Medical Oncology Hematology Consultants
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Medical Oncology Hematology Consultants
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Regional Hematology and Oncology PA
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Regional Hematology and Oncology PA
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Saint Elizabeth Medical Center South
mi
from
Edgewood, KY
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Saint Elizabeth Medical Center South
mi
from
Edgewood, KY
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Saint Elizabeth Fort Thomas
mi
from
Fort Thomas, KY
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Saint Elizabeth Fort Thomas
mi
from
Fort Thomas, KY
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Baptist Health Lexington
mi
from
Lexington, KY
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Baptist Health Lexington
mi
from
Lexington, KY
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Northwest Hospital Center
mi
from
Randallstown, MD
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Northwest Hospital Center
mi
from
Randallstown, MD
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Sparrow Hospital
mi
from
Lansing, MI
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Margaret R Pardee Memorial Hospital
mi
from
Hendersonville, NC
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Margaret R Pardee Memorial Hospital
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Grant Medical Center
mi
from
Columbus, OH
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Grant Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Southern Ohio Medical Center
mi
from
Portsmouth, OH
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Southern Ohio Medical Center
mi
from
Portsmouth, OH
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Medical University of South Carolina
mi
from
Charleston, SC
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials